FDA Drug Master
Files (DMF) Services
An FDA Drug Master File (DMF) is a voluntary, confidential technical reference filed with the FDA's Center for Drug Evaluation and Research that describes the facilities, processes, controls, materials, and quality data used in the manufacture, packaging, or storage of a human drug product or its components. DMFs are filed under 21 CFR 314.420 and allow API manufacturers, excipient suppliers, packaging suppliers, and contract manufacturers to protect trade secrets while still letting the FDA access the technical detail it needs when reviewing a referencing NDA, ANDA, IND, or BLA. The DMF holder issues a Letter of Authorization to each customer who needs to reference the file in their application. Without a properly prepared and maintained DMF — or with a DMF that lapses into "Inactive" status — every NDA, ANDA, or BLA referencing it can be delayed, refused-to-file, or denied approval until the technical record is restored.
A Drug Master File (DMF) is a confidential submission to the FDA containing detailed information about facilities, processes, and materials used in drug manufacturing. FDA Registration Assistance prepares and submits complete, FDA-ready DMFs — protecting your proprietary information while supporting NDA, ANDA, IND, and BLA applications.
What Is a Drug Master File (DMF) & Who Needs One
A Drug Master File (DMF) is a voluntary, confidential submission to the FDA that provides detailed technical information about facilities, processes, materials, or articles used in the manufacturing, processing, packaging, or storage of human drug products. DMFs allow companies to protect proprietary and trade-secret information while enabling the FDA to review critical technical details during the evaluation of NDAs, ANDAs, INDs, and BLAs. FDA Registration Assistance prepares complete, FDA-ready DMFs for drug manufacturers worldwide.
Filed under 21 CFR 314.420 in eCTD format through the FDA Electronic Submissions Gateway, each DMF is assigned a permanent DMF number, listed on the FDA public List of DMFs, and supported by Letters of Authorization the holder issues to referencing applicants. Once "Active," the DMF must be maintained with an Annual Report and amendments for every change in facility, process, material, or ownership.
- Voluntary submission — not required by statute or regulation
- Protects proprietary manufacturing processes and trade secrets
- Referenced by NDA, ANDA, IND, and BLA applications
- FDA reviews DMF only when referenced by an active application
- Must be maintained and updated to remain current and usable
Our Drug Master File (DMF) Services
Everything drug manufacturers need to prepare, submit, and maintain a compliant FDA Drug Master File — handled by experienced FDA regulatory specialists.
DMF Preparation
FDA Registration Assistance compiles and formats all required technical information — including facility details, manufacturing processes, materials, and specifications — into a complete, FDA-acceptable Drug Master File.
FDA Submission & Acknowledgment
FDA Registration Assistance submits your completed DMF to the FDA electronically and tracks the acknowledgment process — ensuring your submission is received and properly filed in the FDA's DMF database.
Letter of Authorization (LOA) Support
FDA Registration Assistance prepares Letters of Authorization (LOAs) enabling authorized applicants to reference your DMF in their NDA, ANDA, IND, or BLA submissions — protecting your confidential information throughout the process.
DMF Maintenance & Amendments
FDA Registration Assistance manages ongoing DMF maintenance — including amendments to reflect changes in facilities, processes, or materials — to keep your DMF current, accurate, and usable for active FDA applications.
Trusted FDA Drug Master File Specialists
Helping API manufacturers, excipient suppliers, and packaging-material producers prepare, submit, and maintain compliant FDA Drug Master Files worldwide.
How Our DMF Preparation & Submission Service Works
A simple four-step process to prepare, submit, and maintain your FDA Drug Master File.
Submit Your Technical Information
Provide your facility details, manufacturing processes, materials, and specifications. FDA Registration Assistance reviews all technical information to determine the appropriate DMF type and content requirements.
DMF Compiled & Reviewed
FDA Registration Assistance compiles all required technical sections, formats the DMF according to FDA guidance, and conducts a thorough quality review to ensure completeness and accuracy before submission.
DMF Submitted to FDA
FDA Registration Assistance submits your completed DMF to the FDA electronically and tracks receipt of the official acknowledgment letter confirming your DMF number and filing date.
LOA Issued & DMF Maintained
FDA Registration Assistance issues Letters of Authorization to authorized applicants and provides ongoing DMF maintenance — keeping your submission current and ready for FDA review when referenced by active applications.
What Every DMF Holder Must Do Under 21 CFR 314.420
A Drug Master File is the holder's standing technical record with the FDA — and the holder carries continuous, concrete responsibilities to keep that record usable for every customer's referencing application.
File the DMF in eCTD Format via FDA ESG
All new DMFs for human drugs must be submitted in electronic Common Technical Document (eCTD) format through the FDA Electronic Submissions Gateway. Paper DMFs and ad-hoc PDF submissions are no longer accepted under FDA's electronic-only requirement.
Designate a U.S. Agent (Foreign Holders)
Foreign DMF holders should designate a U.S. Agent under 21 CFR 314.420(a)(3) to receive FDA correspondence — Information Requests, Discipline Review Letters, and Annual Report reminders. Missed FDA correspondence is a leading cause of DMF deficiencies and downstream ANDA delays.
Maintain Complete CTD Technical Content
Type II API DMFs require full Module 3 / S sections (manufacture, characterization, control, container closure, stability). Type III, IV, and V DMFs require their respective CTD content. Gaps or outdated sections directly cause Information Requests on the referencing application.
Issue Letters of Authorization Per Customer
Each referencing application (NDA, ANDA, IND, BLA) requires its own LOA from the DMF holder identifying the specific applicant, application number, and scope of reference. A generic or blanket LOA will not be accepted by FDA reviewers.
File an Annual Report Every Year
Under 21 CFR 314.420(c), each Active DMF requires an Annual Report — even when no changes have occurred — confirming the LOAs in effect and any minor updates. Missing the Annual Report deadline lapses the DMF into "Inactive" status.
Submit Amendments for Every Material Change
Changes to facility, process, equipment, in-process controls, specifications, container closure, or stability conditions must be filed as DMF amendments under the existing DMF number. Splitting changes across multiple new DMFs creates regulatory confusion and is not permitted.
Pay GDUFA Type II Fees Where Applicable
Type II API DMFs referenced by ANDAs must have a paid GDUFA DMF fee on record before the ANDA referencing them can be received. The fee is set annually by FDA Federal Register notice and is paid through the FDA User Fee System.
Respond Promptly to FDA Deficiency Letters
Information Requests, Discipline Review Letters, and Complete Response Letters issued during review of a referencing application must be answered within the timeframe stated by the FDA. Non-response cascades into ANDA / NDA delay and possible DMF reclassification.
Drug Master File (DMF) vs. Abbreviated New Drug Application (ANDA)
These two FDA submissions are constantly confused — but they have completely different purposes, holders, and outcomes. The DMF supports; the ANDA gets approved.
| Attribute | Drug Master File (DMF) | Abbreviated New Drug Application (ANDA) |
|---|---|---|
| Who Files It | The API manufacturer, excipient supplier, packaging supplier, or contract manufacturer — typically an upstream supplier | The generic finished-dose drug manufacturer — the company that intends to commercialize the generic product |
| What It Represents | Confidential technical data on facilities, processes, and materials — held in reserve at FDA | A full marketing application seeking FDA approval to manufacture and sell a specific generic drug product |
| Required By | Not required by statute — voluntary under 21 CFR 314.420 as a confidentiality vehicle for suppliers | Required by FD&C Act §505(j) and 21 CFR 314.94 for any generic drug seeking U.S. marketing authorization |
| Governing Regulation | 21 CFR 314.420 | 21 CFR 314 Subpart C (§§314.94 et seq.) |
| Primary Function | Provides confidential supplier technical content for FDA to review when the ANDA / NDA cites the DMF | Demonstrates bioequivalence, CMC adequacy, labeling, and facility readiness to obtain FDA marketing approval |
| Outcome of FDA Review | "Active" or "Inactive" status on the FDA public List of DMFs — never "approved" | Approval, Tentative Approval, or Complete Response Letter — and the right to commercialize on approval |
A DMF and an ANDA work together — but they answer different regulatory questions. The DMF is the API supplier saying, "Here is confidentially how I make this active ingredient." The ANDA is the generic drug maker saying, "Here is my finished product, and I'm referencing the API supplier's DMF for the drug substance section." The ANDA gets approved; the DMF does not. A complete and Active DMF is a prerequisite for an ANDA referencing it to be received and reviewed — and a deficient DMF can stall every ANDA that depends on it. Most generic supply chains require both: a Type II API DMF on file from the supplier, and an ANDA filed by the generic-drug holder that names the DMF and pays the GDUFA Type II DMF fee.
In-House DMF Preparation vs. FDA Registration Assistance
A DMF is half regulatory document, half technical dossier. eCTD formatting, CTD module placement, and FDA correspondence are specialist work — and the wrong filing delays every customer who references it.
| Factor | In-House / DIY Preparation | Recommended FDA Registration Assistance |
|---|---|---|
| Cost | Internal regulatory staff time, eCTD publishing software licenses, GDUFA fee management, and rework after FDA deficiency letters | Custom quote — covers eCTD publishing, FDA ESG submission, LOA management, Annual Reports & deficiency response |
| Availability | Depends on which internal team owns the file — often shared between R&D, QA, and a freelance regulatory consultant | Dedicated FDA regulatory specialist owns the DMF lifecycle and FDA correspondence on your behalf |
| Domain Expertise | Requires fluency in 21 CFR 314.420, eCTD specifications, FDA DMF guidance, GDUFA fee mechanics, and Module 3 / S CTD authoring | 15+ years across Type II API, Type III packaging, Type IV excipient, and Type V reference DMF filings |
| Risk of Failure | High — incomplete CTD sections, wrong DMF type, missing LOA template, or eCTD validation errors are common | Pre-submission audit catches CTD/eCTD issues before filing; FDA deficiency responses included in maintenance |
| Confirmation & Handling | You parse the FDA acknowledgment letter, monitor the public List of DMFs yourself, and chase LOAs manually | Acknowledgment letter, DMF number, and FDA public-list status delivered and monitored on your behalf |
| Annual Report & Update Tracking | You must self-track the 21 CFR 314.420(c) Annual Report deadline and every amendment trigger | Calendared Annual Reports, automatic amendment filings, and proactive deficiency-letter response |
DMF preparation is unforgiving: a single misplaced CTD section, a missing LOA template, an unpaid GDUFA fee, or a missed Annual Report can convert an "Active" DMF into "Inactive" — blocking every customer's ANDA. In-house teams typically lack dedicated eCTD publishing tooling and U.S.-time-zone FDA correspondence coverage. FDA Registration Assistance owns the DMF lifecycle end-to-end: preparation, ESG submission, LOA issuance, Annual Reports, amendments, and deficiency-letter response — so the DMF stays Active and every referencing application moves forward without supplier-side delay.
Free / Friend / Customer Filing vs. FDA Registration Assistance
The FDA charges no fee to file a Type III, IV, or V DMF — and the GDUFA Type II fee is a separate FDA charge unrelated to professional preparation. But "free" or borrowed filings expose the holder to ownership and FDA-correspondence risks that are very expensive to unwind.
| Factor | Free / Friend / Customer-Filed | Recommended FDA Registration Assistance |
|---|---|---|
| Government Fee | $0 for Types III, IV, V; GDUFA Type II API DMF fee applies when referenced by an ANDA (paid separately to FDA) | $0 government fee for Types III/IV/V + custom service fee; GDUFA Type II fee handled and tracked on the holder's behalf |
| Pros | No out-of-pocket service fee if a friend or downstream customer is willing to file on your behalf | DMF filed under your legal entity, your U.S. Agent, with eCTD validation, FDA correspondence handling and ongoing maintenance |
| Cons | Whoever files the DMF becomes the holder in FDA's records — and only the holder can issue LOAs, amend the file, or receive FDA correspondence. Recovering ownership requires a formal Transfer of Ownership submission and FDA acknowledgment, and downstream customers can lose access in the interim. | Predictable scope, correct holder identity from day one, eCTD validation, calendared Annual Reports, and deficiency-letter response included |
| Best For | No realistic business case — the DMF must belong to the supplier whose facility and process it describes | Every API, excipient, packaging-material, and contract-manufacturing supplier whose customers need to reference confidential CMC content in FDA applications |
"Free" filings — by a friend, an agent, or a downstream customer — almost always result in the DMF being assigned to the wrong legal entity. Because LOA rights, amendments, and FDA correspondence all attach to the named holder, a wrongly-attributed DMF blocks the actual supplier from controlling its own confidential data. A professional filing under the correct entity, with eCTD validation and ongoing maintenance, is the only path that protects both ownership and downstream customer applications.
Drug Master File Terms You Will Encounter
A quick reference of the technical terms, document types, and submission systems used throughout the FDA Drug Master File process.
The permanent four- or five-digit identifier the FDA assigns to every Drug Master File upon submission. The DMF number appears on the FDA public List of DMFs and is referenced by every LOA and amendment for the life of the file.
The most common DMF type — confidential technical content describing the manufacture, characterization, and control of an active pharmaceutical ingredient or its key intermediate. Subject to the GDUFA Type II API DMF fee when referenced by an ANDA.
Confidential technical content describing primary or secondary drug-product packaging materials — composition, manufacturing process, extractables/leachables data, and specifications.
Confidential technical content describing an excipient, colorant, flavor, essence, or other material used in the preparation of a drug product — including manufacturing process and quality specifications.
A residual category accepted by FDA only when no other DMF type fits — for example, certain manufacturing-site or testing-laboratory reference information used by multiple applications.
A document from the DMF holder authorizing a specific applicant to reference a specific DMF in a specific FDA application. Without a current LOA on file, FDA will not review the DMF in connection with the referencing application.
A yearly submission required under 21 CFR 314.420(c) confirming the LOAs in effect and any minor updates since the prior filing. Missing the Annual Report lapses the DMF into "Inactive" status.
The XML-based ICH-aligned electronic format FDA requires for all new human-drug DMF submissions and amendments — transmitted through the FDA Electronic Submissions Gateway.
The secure FDA transport system used to submit eCTD DMFs, amendments, and Annual Reports. ESG accounts must be set up before any DMF filing.
A user fee under the Generic Drug User Fee Amendments paid by the holder of a Type II API DMF that will be referenced by an ANDA. Fee amounts are set each fiscal year by FDA Federal Register notice.
The FDA's public quarterly listing of every DMF by number, type, subject, holder, and status (Active / Inactive). Referencing applicants use this list to verify DMF identity and status before citing it in an application.
A formal DMF amendment under 21 CFR 314.420(c)(7) used when the legal entity that holds the DMF changes — typically through acquisition, divestiture, or corporate reorganization. The DMF number is retained; only the holder changes.
Why DMFs Fail FDA Review or Lapse Into "Inactive" Status
After 15+ years of preparing and maintaining DMFs, these are the most frequent reasons a Drug Master File becomes a bottleneck for the referencing NDA, ANDA, or BLA.
Missed Annual Report (Lapsed to "Inactive")
21 CFR 314.420(c) requires an Annual Report each year, even when nothing has changed. Skipping a single year lapses the DMF into "Inactive" status — and every ANDA, NDA, or BLA referencing it is paused until the file is reactivated.
Incomplete CTD Module 3 / S Sections
Type II API DMFs require detailed CTD Module 3.2.S sections covering manufacture, characterization, control, container closure, and stability. Missing sub-sections, missing degradation impurities, or missing in-process controls generate FDA Information Requests against every referencing ANDA.
Unpaid GDUFA Type II API DMF Fee
Type II API DMFs referenced by ANDAs must have the GDUFA DMF fee paid before the referencing ANDA can be received. An unpaid fee on a Type II DMF causes the ANDA to be refused-to-file and removes the DMF from the public "available for reference" list.
Wrong or Missing Letter of Authorization
Every referencing application needs an LOA that names the specific applicant, application number, and scope. Generic or blanket LOAs are rejected, and missing LOAs mean the FDA cannot review the DMF content in connection with the referencing NDA/ANDA/BLA.
eCTD Validation Errors
FDA's eCTD validation tools reject submissions with broken study tagging files, missing leaf elements, wrong eCTD lifecycle operators, or invalid module placement. A failed validation means the DMF or amendment never enters the review queue.
Foreign Holder Without a U.S. Agent
Foreign DMF holders without a designated U.S. Agent routinely miss FDA Information Requests, deficiency notices, and Annual Report reminders. Missed correspondence is one of the leading root causes of "Inactive" status and downstream ANDA delay.
Opening a New DMF Instead of Amending
For changes to facility, process, equipment, or specifications, the holder must amend the existing DMF — not open a new DMF for the same subject. Duplicate DMFs create confusion in referencing applications and are routinely flagged by FDA reviewers.
Claiming "FDA-Approved" Based on the DMF
FDA does not approve DMFs and explicitly does not confirm their existence to third parties under 21 CFR 314.420(d). Marketing copy claiming "FDA approved our DMF" or "FDA approved our API" is misleading and triggers compliance issues for both the supplier and downstream applicants.
Complete FDA Drug Registration Solutions
We offer a full range of FDA registration and compliance services to help your facility and shipments meet all U.S. regulatory requirements.
Drug Establishment Registration
Register your foreign or domestic drug manufacturing, repacking, or relabeling facility with the FDA — $449/year, U.S. Agent included.
Labeler Code Registration
Obtain your FDA Labeler Code — required to identify your company on drug product labels and NDC numbers. $349 per company.
NDC Code / Product Code
Register your National Drug Code (NDC) and product codes with the FDA — $199 per product, mandatory for all U.S. drug products.
Drug Label & Ingredient Review
Ensure your drug product labels and ingredient declarations meet all FDA labeling requirements — $249 per label review.
DUNS Request Assistance
Obtain your DUNS Number required for FDA Drug Establishment Registration and federal compliance — filed accurately on your behalf.
Drug / OTC U.S. Agent Services
Designate a U.S. FDA Agent for your foreign drug establishment — legally required for all foreign drug facilities registered with the FDA.
FDA Drug Listing Certificate
Obtain your official FDA Drug Listing Certificate confirming your drug product is registered and listed with the U.S. Food and Drug Administration.
FDA Drug Master Files (DMF)
Submit an FDA Drug Master File (DMF) to protect confidential manufacturing information while supporting drug product applications and registrations.
Drug Import Alert Removal
Get expert help resolving FDA drug import alerts and detentions to restore your drug products' ability to enter the United States.
Frequently Asked Questions — FDA Drug Master Files (DMF)
Find answers to the most common questions about FDA Drug Master Files, DMF preparation, submission, and how FDA Registration Assistance supports drug manufacturers worldwide.
What is a Drug Master File (DMF)?
A Drug Master File (DMF) is a voluntary, confidential submission to the FDA that provides detailed technical information about facilities, processes, materials, or articles used in the manufacturing, processing, packaging, or storage of human drug products. DMFs allow companies to protect proprietary information while enabling the FDA to review critical technical details when evaluating drug applications such as NDAs, ANDAs, INDs, and BLAs.
Is a DMF required by the FDA?
No. Drug Master Files are not required by statute or regulation. They are voluntary submissions. However, DMFs are commonly used by drug manufacturers, excipient suppliers, packaging material manufacturers, and contract manufacturers to protect proprietary information while supporting their customers' FDA drug applications. FDA Registration Assistance helps companies determine when a DMF is appropriate for their regulatory strategy.
Does the FDA approve or disapprove DMFs?
No. The FDA does not approve or disapprove Drug Master Files. The FDA reviews the technical content of a DMF only when it is referenced by an active drug application such as an NDA, ANDA, IND, or BLA. The DMF itself is not subject to a separate approval process. FDA Registration Assistance ensures your DMF is complete and properly formatted so it is ready for FDA review when referenced.
What types of information are included in a DMF?
A DMF typically includes detailed information about manufacturing facilities and equipment, manufacturing processes and controls, raw materials and excipients, packaging materials, specifications and testing methods, and stability data. The specific content depends on the DMF type. FDA Registration Assistance prepares all required technical sections in FDA-acceptable format.
Who can reference a DMF?
Only parties authorized by the DMF holder through a Letter of Authorization (LOA) may reference the DMF in their FDA drug application. The LOA must be provided to the FDA and included with the referencing application. FDA Registration Assistance prepares LOAs for authorized applicants and manages the authorization process on behalf of DMF holders.
What applications can reference a DMF?
Drug Master Files may be referenced by New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Investigational New Drug applications (INDs), Biologics License Applications (BLAs), and other FDA submissions that require review of manufacturing, facility, or material information. FDA Registration Assistance helps identify the appropriate DMF type for each client's regulatory context.
What are the different types of DMFs?
The FDA recognizes several DMF types: Type II (drug substance, drug substance intermediate, or material used in synthesis), Type III (packaging material), Type IV (excipient, colorant, flavor, essence, or material used in preparation), and Type V (FDA-accepted reference information). Type II DMFs for active pharmaceutical ingredients (APIs) are the most commonly submitted. FDA Registration Assistance prepares all standard DMF types.
How long does DMF preparation take?
The time required to prepare a Drug Master File depends on the complexity of the manufacturing process, the volume of technical documentation available, and the DMF type. FDA Registration Assistance provides a timeline estimate after reviewing your technical information. Most standard DMFs can be compiled and submitted within 4–8 weeks of receiving complete documentation from the client.
How much does DMF preparation cost?
FDA Registration Assistance provides custom pricing for Drug Master File preparation and submission services. The fee depends on the DMF type, the complexity of the manufacturing information, and the scope of ongoing maintenance required. Contact FDA Registration Assistance directly for a personalized quote based on your company's technical documentation and regulatory requirements.
Do DMFs need to be updated?
Yes. Drug Master Files must be maintained and updated to remain current and usable. Any changes to manufacturing facilities, processes, materials, specifications, or equipment must be reflected in the DMF through an amendment submission. Outdated or inaccurate DMFs can cause delays in FDA review of referencing applications. FDA Registration Assistance provides ongoing DMF maintenance and amendment support.
What is a Letter of Authorization (LOA)?
A Letter of Authorization (LOA) is a document issued by the DMF holder authorizing a specific applicant to reference the DMF in their FDA drug application. Without a valid LOA, the FDA will not review the DMF in connection with the referencing application. FDA Registration Assistance prepares LOAs on behalf of DMF holders and manages the authorization process with referencing applicants.
Can foreign companies submit a DMF to the FDA?
Yes. Foreign drug manufacturers, excipient suppliers, and packaging material manufacturers can submit Drug Master Files to the FDA. Foreign DMF holders may be required to have a U.S. Agent for FDA correspondence. FDA Registration Assistance assists both domestic and international companies with DMF preparation, submission, and ongoing maintenance.
How is a DMF submitted to the FDA?
Drug Master Files are submitted to the FDA electronically through the FDA's Electronic Submissions Gateway (ESG) in the appropriate format. Upon receipt, the FDA issues an acknowledgment letter confirming the DMF number and filing date. FDA Registration Assistance handles the complete electronic submission process and tracks acknowledgment on behalf of clients.
What happens after the DMF is submitted?
After submission, the FDA issues an acknowledgment letter with the assigned DMF number. The DMF content is not reviewed by the FDA until it is referenced by an active drug application. At that point, the FDA may issue a deficiency letter if information is incomplete or unclear. FDA Registration Assistance responds to FDA queries and manages amendments to resolve any deficiencies promptly.
Can FDA Registration Assistance respond to FDA DMF deficiency letters?
Yes. If the FDA issues a deficiency letter regarding your DMF content, FDA Registration Assistance prepares and submits a complete response — addressing each deficiency with the required technical information, clarifications, or amendments. Timely and thorough responses to FDA deficiency letters help prevent delays in the approval of the applications referencing your DMF.
Does FDA Registration Assistance assist with the full drug registration process?
Yes. In addition to Drug Master File services, FDA Registration Assistance provides complete drug establishment registration, drug listing, NDC code assignment, labeler code registration, DUNS request assistance, U.S. Agent services, drug label review, and FDA Drug Listing Certificate services — a full-service FDA compliance solution for drug manufacturers worldwide.
Why is DMF pricing custom-quoted instead of a flat fee, and how does it fit alongside Drug Establishment Registration, Labeler Code, and NDC services?
DMFs are custom-quoted because the workload varies dramatically by DMF type, technical documentation volume, eCTD complexity, and ongoing maintenance scope. A Type V reference DMF differs in effort from a Type II API DMF with hundreds of pages of synthesis, validation, and stability data. The DMF is also separate from the routine establishment-level services most drug companies need: Drug Establishment Registration at $449/year (under 21 CFR Part 207, with U.S. Agent included), Drug Labeler Code at $349 (under 21 CFR 207.33), NDC Code / Product Code at $199 per product, and Drug Label & Ingredient Review at $249 per label. The DMF is added on top of that baseline for companies that supply APIs, excipients, or packaging materials to NDA/ANDA holders.
Can a friend or unrelated party file my Drug Master File for me?
Technically yes, but it is strongly discouraged. The DMF is permanently bound to the holder named in the cover letter — DMF number, ownership, and Letter of Authorization rights all belong to the legal entity in the submission. A friend or unrelated party filing under their own ESG account or company name would effectively own your DMF, and the FDA will only correspond with that holder. Transferring DMF ownership later requires a formal Transfer of Ownership submission and FDA acknowledgment. A professional service files under your verified legal entity from day one, so the DMF number, the LOAs, and all future amendments stay with your company.
What happens if I do not respond to an FDA deficiency letter on my DMF?
The application that referenced your DMF will be delayed or rejected — and your DMF may be flagged as inactive, blocking all current and future LOAs. The FDA issues Information Requests, Discipline Review Letters, or Complete Response Letters when DMF content has gaps. Failure to respond within the stated timeframe causes the referencing NDA/ANDA/BLA to be placed on hold, refused-to-file, or denied approval — and your customer relationships with the referencing applicants take the damage. FDA Registration Assistance monitors deficiency communications and responds on your behalf as part of ongoing maintenance.
How do I update or change information in an existing DMF?
File an amendment to the existing DMF through the FDA Electronic Submissions Gateway in eCTD format under the same DMF number — never open a new DMF for the same product or facility. Amendments are required for any change to manufacturing facilities, processes, materials, specifications, equipment, ownership, U.S. Agent, or contact information, plus an Annual Report each year under 21 CFR 314.420(c). FDA Registration Assistance prepares and files all amendments and Annual Reports to keep the DMF in 'Active' status.
Do I need a DMF to sell my OTC drug, supplement, or finished product on Amazon?
No. DMFs support FDA applications (NDA, ANDA, IND, BLA) — not retail marketplaces. Amazon's drug categories require a Drug Establishment Registration, a Labeler Code, an NDC, and compliant labeling — not a DMF. DMFs are for upstream suppliers (API, excipient, packaging) whose customers file NDAs or ANDAs.
Does having a DMF mean my drug, API, or facility is FDA-approved?
No. A DMF is a confidential technical reference file — not an FDA approval, clearance, or endorsement. 21 CFR 314.420(d) prohibits the FDA from confirming or denying the existence of a DMF, and any marketing claim that "FDA approved" a DMF or the underlying API/material is misleading and unsupported. FDA approves the referencing NDA, ANDA, or BLA — not the DMF itself.
What is the difference between a Type II API DMF and an ANDA?
A Type II DMF describes the active pharmaceutical ingredient (API) — its synthesis, controls, and manufacturing facility — and is filed by the API manufacturer. An ANDA is filed by the finished-dose drug manufacturer seeking approval to market a generic finished product. The ANDA typically references the API supplier's Type II DMF for the drug-substance section. Both filings are required for most generic drug approvals — the DMF protects the API maker's trade secrets, the ANDA gets the finished product approved.
Are excipient and packaging-material DMFs subject to GDUFA fees?
No. Under the Generic Drug User Fee Amendments (GDUFA), only Type II DMFs for APIs referenced by ANDAs incur a DMF fee. Type III packaging DMFs, Type IV excipient DMFs, and Type V reference DMFs are not subject to the GDUFA Type II DMF fee. The GDUFA Type II DMF fee is set annually by FDA and published in the Federal Register.
How do I verify whether a Drug Master File is active and listed with the FDA?
Use the FDA's public "List of DMFs" on FDA.gov — it lists every DMF by number, type, subject, holder, and status (Active or Inactive). The list is refreshed quarterly. A DMF marked "Inactive" cannot be relied on by referencing applicants until reactivated through an amendment and FDA acknowledgment.
Does my DMF need a U.S. Agent if my company is outside the United States?
Yes, in practice. Foreign DMF holders should designate a U.S. Agent under 21 CFR 314.420(a)(3) to receive FDA correspondence — Information Requests, deficiency letters, and Annual Report reminders. Without a U.S. Agent or a U.S. contact, FDA correspondence delays will cause LOAs to fail and referencing applications to stall. The U.S. Agent for a foreign DMF must have a verifiable U.S. street address.
Can a single Drug Master File cover multiple APIs or multiple facilities?
Generally no. A DMF covers one subject — typically one drug substance, one packaging system, or one excipient — manufactured at one or more facilities controlled by the same holder. Different APIs, different packaging materials, or different unrelated facilities each require their own DMF number.
What is the difference between an Active DMF and an Inactive DMF?
An "Active" DMF is current — Annual Reports are filed, amendments are up to date, and the DMF is available for referencing applicants. An "Inactive" DMF either was withdrawn by the holder, deemed deficient by FDA, or had its Annual Report lapse. Inactive DMFs cannot be referenced by ANDAs or other applications until reactivated through a complete amendment and FDA acknowledgment.
How do I transfer ownership of a DMF when my company is acquired?
File a Transfer of Ownership submission to the existing DMF number — including a letter from the former holder confirming the transfer, a letter from the new holder accepting responsibility, and updated contact information. FDA acknowledges the transfer in writing; the DMF number stays the same, but all future correspondence, LOAs, and amendments are issued by the new holder. FDA Registration Assistance prepares and files Transfer of Ownership submissions to keep the DMF and its existing LOAs intact.
Can I use a DMF to support a Type A or Type B Pre-IND meeting with the FDA?
Yes, indirectly. A DMF is not the meeting submission itself, but the Pre-IND sponsor or applicant can include a Letter of Authorization referencing the DMF so the FDA reviewer can access the supplier's confidential CMC information during the pre-IND review. The DMF holder must issue an LOA covering the specific application or meeting scope.
Get Your Drug Master File Prepared Today
Submit your facility and manufacturing details and FDA Registration Assistance will prepare and submit your complete Drug Master File to the FDA — protecting your proprietary information while supporting your drug applications.
Thank You for Reaching Out!
We've received your message and will get back to you within 24 hours. If you need immediate assistance, please call us directly.